Dr Neal Cutler has continuously dedicated himself to the cause of advancing medical science and assisting the development of life-changing medicines. He has steadily built up a reputation for both his own academic contributions and his role as the head of Worldwide Clinical Trials, one of the world’s leading full-service contract research organisations. The company provides full-service drug development services, ranging from early phase and bioanalytical science solutions all the way through to the late phase and post-approval stages. Throughout his career, Cutler has been a key contributor to the development and design of around 200 compounds.

Cutler founded the company more than 30 years ago, and under his astute expansion strategy it has exhibited impressive growth rates. Its portfolio of infrastructure and talent now spans 60 countries, employing more than 1,600 professionals throughout a wide network of international offices across North and South America, Eastern and Western Europe, and Asia. It is thanks to Cutler’s operational acumen that Worldwide Clinical Trials has been able to grow so quickly while remaining flexible.

Cutler has the rare combination of noteworthy technical expertise and natural leadership qualities. He is a board-certified psychiatrist who has authored more than 275 publications, spanning topics including clinical pharmacology, ageing, Alzheimer’s disease, schizophrenia and diabetes. Among his many contributions to medical science is his development of a methodology for a type of exploratory study, known as ‘dynabridge study’. This has led to a greater understanding of compounds in the brain, and has paved the way for the development of numerous new treatments.

Cutler’s people-centric approach combined with his in-depth knowledge of the industry has made him stand out as an exceptional leader in his sector. It is his keen oversight that has led to Worldwide Clinical Trials becoming the benchmark for quality in the global market.